Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Withdrawal Symptoms Clear all
Completed Phase 4 Interventional Results available

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jun 11, 2026, 2:16 AM EDT
Completed No phase listed Observational

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

NCT05438641
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
BZDP-Sparing Protocol, BZDP-Based Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 11, 2026, 2:16 AM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jun 11, 2026, 2:16 AM EDT
Completed No phase listed Observational

A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons

NCT00340015
View directory record Official record
Conditions
Death, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 71 Years
Enrollment
566,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Patch for Marijuana Withdrawal

NCT01400243
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Nicotine, Placebo Patch
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

NCT00922272
View directory record Official record
Conditions
Schizophrenia and Predominant Negative Symptoms
Interventions
SPD489 (lisdexamfetamine dimesylate), Placebo matching SPD489 (lisdexamfetamine dimesylate)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing Opioid Care Practices Using CPV Patient Simulation Modules

NCT04080037
View directory record Official record
Conditions
Pain, Pain, Acute, Pain, Chronic, Pain, Neuropathic, Opioid-use Disorder, Opioid Abuse and Addiction, Opioid Withdrawal
Interventions
Quality IQ Patient Simulations
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

NCT02013622
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Cerritos, California • Chula Vista, California • Costa Mesa, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

NCT05533008
View directory record Official record
Conditions
Hemodialysis
Interventions
CR845 0.5 mcg/kg, Placebo
Drug · Other
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Bridgeport, Connecticut • Hartford, Connecticut • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional

Heart Obesity Prevention Education

NCT02092545
View directory record Official record
Conditions
Obesity
Interventions
Ketogenic diet
Other
Lead sponsor
Tampa General Hospital
Other
Eligibility
25 Years to 64 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

NCT00475189
View directory record Official record
Conditions
Pelvic Pain, Headaches, Emotional
Interventions
loestrin 24/4 vs loestrin 1/20, loestrin 1/20
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Jun 11, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Placebo, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

NCT02643355
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Olanzapine, Clonidine
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jun 11, 2026, 2:16 AM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Effectiveness of Bupropion in Treating Marijuana Dependent Individuals

NCT00142870
View directory record Official record
Conditions
Marijuana Abuse, Substance-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Jun 11, 2026, 2:16 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pioglitazone to Treat Opioid Withdrawal Symptoms

NCT01517165
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jun 11, 2026, 2:16 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Multiple Concussions in Retired NHL Players

NCT02746523
View directory record Official record
Conditions
Cognitive Deficits, Proprioceptive Disorders
Interventions
Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
Other · Genetic
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Jun 11, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Effect of PP-01 on Cannabis Withdrawal Syndrome

NCT05494437
View directory record Official record
Conditions
Cannabis Withdrawal
Interventions
PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin
Combination Product · Drug
Lead sponsor
PleoPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Glendale, California • Lemon Grove, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Jun 11, 2026, 2:16 AM EDT